Claudins (CLDNs) are a family of integral membrane proteins central to the formation of tight junctions, structures that are involved in paracellular transport and cellular growth and differentiation, and are critical for the maintenance of cellular polarity. Recent studies have provided evidence that CLDNs are aberrantly expressed in diverse types of human cancers, including hepatocellular carcinomas (HCCs). However, little is known about how CLDN expression is involved in cancer progression. In this study, we show that CLDN1 has a causal role in the epithelial-mesenchymal transition (EMT) in human liver cells, and that the c-Abl-Ras-Raf-1-ERK1/2 signaling axis is critical for the induction of malignant progression by CLDN1. Overexpression of CLDN1 induced expression of the EMT-regulating transcription factors Slug and Zeb1, and thereby led to repression of E-cadherin, b-catenin expression, enhanced expression of N-cadherin and Vimentin, a loss of cell adhesion, and increased cell motility in normal liver cells and HCC cells. In line with these findings, inhibition of either c-Abl or ERK clearly attenuated CLDN1-induced EMT, as evidenced by a reversal of N-cadherin and E-cadherin expression patterns, and restored normal motility. Collectively, these results indicate that CLDN1 is necessary for the induction of EMT in human liver cells, and that activation of the c-Abl-Ras-Raf-1-ERK1/2 signaling pathway is required for CLDN1-induced acquisition of the malignant phenotype. The present observations suggest that CLDN1 could be exploited as a biomarker for liver cancer metastasis and might provide a pivotal point for therapeutic intervention in HCC.
INTRODUCTION
Hepatocellular carcinoma (HCC) is the third-leading cause of cancer deaths and the fifth-most common cancer in the world. 1, 2 The prognosis of HCC is very poor; the 5-year survival rate worldwide is o5%, mainly because of a high potential for vascular invasion, metastasis and recurrence, even after surgical resection. 3 HCC commonly metastasizes to lungs, lymph nodes, adrenal gland and bones, including the skull. 4 Like other cancers, HCC metastasis is a multistep process that includes tumor cell invasion into the surrounding tissues, entry of tumor cells into the systemic circulation (intravasation), survival of cells in the circulation, extravasation of cells at distant organs and, finally, the formation of secondary tumors. 5 However, little is known about the molecular mechanisms by which primary tumor cells metastasize to other organs.
There is a growing understanding that epithelial-mesenchymal transition (EMT) can contribute to invasive and metastatic tumor growth. 6, 7 During EMT, the expression levels of the adhesion molecule E-cadherin are decreased, whereas N-cadherin and Vimentin levels are increased. These molecular alterations may cause dysfunctional cell-cell adhesion and loss of cell-cell junctions, thereby allowing dissemination of tumor cells from the primary sites. In addition to adhesion molecules, tight junction proteins also appear to have critical roles in the neoplastic process via their roles as couplers of the extracellular milieu to intracellular signaling pathways and the cytoskeleton. 8, 9 Tight junctions are highly regulated areas of adhesion between epithelial and endothelial cells. 10 They are the most apical component of the lateral plasma membrane and are connected to the actin cytoskeleton. 11 Tight junctions form a barrier that separates apical and basolateral fluid compartments on opposite sides of the epithelial cell layer and prevent paracellular movement of substances. Because tight junctions are located between epithelial cells, where they also serve an adhesive function, as well as between endothelial cells, where they regulate the travel of molecules and inflammatory cells, they represent a critical barrier that cancer cells must overcome in order to penetrate and initiate metastasis. 12 Alterations in tight junction permeability may also allow increased diffusion of nutrients and other factors critical for tumor growth and survival. 13 In addition, the loss of tight junction integrity may be an important step in the development of a progressive or metastatic phenotype. 13, 14 However, the molecular mechanisms underlying this process remain unknown.
Claudins (CLDNs) are a family of integral membrane proteins central to the formation of tight junctions. 15, 16 In addition to regulating paracellular transport, as noted above, these structures are critical for the maintenance of cellular polarity and are involved in cellular growth and differentiation. 17 CLDNs were originally thought to be simple sealing proteins at the tight junction, as suggested by the name claudin, which derives from the Latin word 'claudere' meaning to close. Notably, recent studies have shown that CLDNs are aberrantly expressed in diverse types of human cancers, including HCCs. 18, 19 However, CLDNs remain incompletely characterized and their role in tumor malignancy is poorly understood. Previously, we have shown that CLDN1 promotes invasive property in HCC cells. 20 In the current study, in line with the previous observations, we found that CLDN1 induces EMT through activation of the transcription factors Slug and Zeb1, thereby promoting acquisition of an invasive phenotype in normal liver cells and HCC cells. We also found that the expression levels of Slug and Zeb1 are regulated through the c-Abl-Ras-Raf-1-ERK (extracellular signal-regulated kinase) signaling axis. Taken together, our results suggest that the tight junction protein, CLDN1, has a pivotal role in HCC metastasis through induction of the EMT program.
RESULTS

CLDN1 promotes mesenchymal transformation in HCC
Our previous study showed that CLDN1 promotes invasiveness in human liver Chang cells. 20 To extend these observations, we investigated whether CLDN1-induced invasiveness is associated with the mesenchymal transformation of liver cells. To examine this possibility, we analyzed epithelial and mesenchymal cell markers in Chang cell clones (C no. 1, C no. 11 and C no. 13) that stably overexpress CLDN1 and have invasive trait than their parental Chang cells (Supplementary Figure S1A) . As shown in Figure 1a and Supplementary Figure 1B , western blot analyses revealed a decrease in expression levels of b-catenin, E-cadherin and an increase in the expression levels of the mesenchymal cell markers N-cadherin and Vimentin in CLDN1-expressing Chang cell clones, compared with normal liver (parental) Chang cells. These results were confirmed by immunocytochemistry analyses, which also showed lower expression of b-catenin, E-cadherin and higher expression of N-cadherin in CLDN1-expressing Chang cells than in control cells (Figure 1b and Supplementay Figure S1C ). In addition, treatment with si-RNA targeting of CLD1 in CLDN1-expressing Chang cells restored the expression levels of E-cadherin, N-cadherin and Vimentin to the levels of parental Chang cells (Supplementay Figure S1D ). In line with these results, the expression levels of the EMT-regulating transcription factors Slug and Zeb1, but not Snail, were increased by overexpression of CLDN1 (Figure 1c) . Intriguingly, however, cell morphology was not altered by CLDN1 expression (data not shown). Taken together, these data suggest that CLDN1 promotes acquisition of an invasive phenotype in Chang cells by inducing epithelialmesenchymal transition.
CLDN1 induces mesenchymal transformation through the EMT transcription factors Slug and Zeb1 Because CLDN1 overexpression led to an increase in the transcription factors Slug and Zeb1, but not Snail, we examined whether CLDN1 promotes mesenchymal transformation in Chang cells through upregulation of Slug and Zeb1. To this end, we treated CLDN1-expressing Chang cells (C no. 13) with small interfering RNA (siRNA) targeting Snail, Slug or Zeb1. Notably, downregulation of Slug or Zeb1 increased the expression of b-catenin and decreased the expression of Vimentin and N-cadherin (Figures 2a and b) . In experiments performed in parallel, we found that treatment with siRNA targeting of Slug or Zeb1 attenuated the invasive properties of CLDN1-expressing Chang cells (Figures 2a and b) . In contrast, downregulation of Snail had no effect on invasiveness or b-catenin, Vimentin or N-cadherin expression levels (Figure 2c ). Taken together, these results suggest that CLDN1 promotes mesenchymal transformation through upregulation of Slug and Zeb1 in Chang cells. 21 Accordingly, we next attempted to assess whether MAPK activation is involved in CLDN1-mediated mesenchymal transformation. We found that ERK1/2 and c-Jun N-terminal kinase (JNK)-1/2 are more phosphorylated in CLDN1-expressing Chang cells (C no. 1, C no. 11 and C no. 13), compared with control Chang cells (Figure 3a) . Levels of the active form of Ras, measured using Raf-1 Ras-binding domain agarose assays, were increased in CLDN1-expressing Chang cells without a corresponding change in the total amount of Ras (Figure 3b ), suggesting that CLDN1 activates Ras-Raf-1-ERK signaling. Consistent with these results, treatment with the ERK inhibitor U0126 led to an increase in the expression of b-catenin and a decrease in the levels of the mesenchymal markers, N-cadherin and Vimentin, in CLDN1-expressing Chang cells (C no. 13) (Figure 3c ). These results were confirmed by immunocytochemistry, which also showed that inhibition of ERK signaling caused an increase in b-catenin and a decrease in N-cadherin (Figure 3d) . Parallel experiments showed that treatment with the ERK inhibitor U0126 led to a decrease in the EMT-regulating transcription factors, Slug and Zeb1 (Figure 3e) , and suppressed the invasiveness of CLDN1-expressing Chang cells (Figure 3f ). Also, treatment with siRNA targeting of ERK1 or ERK2 markedly suppressed invasive trait in CLDN1-expressing Chang cells (Supplementary Figure S2A) . However, treatment with siRNA targeting JNK1/2 or JNK inhibitor or p38 MAPK inhibitor had no effect on the invasiveness of Chang cells (Supplementary Figure  S2B and C), indicating that JNK and p38 MAPK signaling are not involved in CLDN1-mediated mesenchymal transformation. Taken together, these results suggest that CLDN1 induces EMT through Ras-Raf-1-ERK signaling in Chang cells.
C#1
CLDN1 induces EMT through the c-Abl-Ras-Raf-1-ERK signaling pathway We previously showed that c-Abl activation was required for CLDN1-induced invasiveness in HCCs. 20 To determine whether ERK1/2 signaling is regulated by c-Abl, we treated CLDN1-expressing Chang cells (C no. We next verified that the c-Abl-Ras-Raf-1-ERK1/2 signaling axis also participates in EMT induction and promotion of invasiveness in human HCC cell lines as it does in Chang normal liver cell line. In our previous study, we observed that HCC cell lines (SNU-354, SNU-423 and SNU-449) that expressed higher levels of CLDN1 showed more invasive trait than other HCC cell lines (SNU-398 and SNU-475) that expressed relatively low levels of CLDN1. 20 In parallel with the data, SNU475 HCC cells expressed lower levels of b-catenin, E-cadherin and higher levels of N-cadherin, Vimentin and CLDN1, compared with Chang cells (Supplementary Figure  S2D) . Thus, in these mesenchymal HCC cells (SNU-354, SNU-423 and SNU-449), we examined the effect of downregulation of c-Abl on expression levels of EMT transcription factors Slug, Zeb1 and Snail. As expected, treatment with siRNA targeting of c-Abl caused a decrease of Slug and Zeb1 expression levels but did not affect Snail expression both in mRNA and protein (Figure 5a and Supplementary Figure S3A ). In parallel with these results, we found that downregulation of c-Abl suppressed the invasiveness of all three human HCC cell lines tested. Moreover, treatment with the ERK inhibitor U0126 decreased expression of Slug and Zeb1, but not Snail, both in mRNA and protein levels ( We next examined whether c-Abl acts through Slug and Zeb1 to induce mesenchymal transformation. To this end, we treated the three human HCC cell lines (SNU-354, SNU-423 and SNU-449) with siRNA targeting of Snail, Slug or Zeb1. Notably, treatment with siRNA targeted to Slug or Zeb1 effectively suppressed invasiveness in all three human HCC cell lines (Figures 5c and d) . In contrast, treatment with siRNA targeted to Snail had no effect on invasiveness in all three human HCC cell lines (Figure 5e ). In parallel with this result, treatment with siRNA targeted to Slug or Zeb1 effectively caused to increase the expression of epithelial cell marker E-cadherin, b-catenin and decrease mesenchymal cell markers, N-cadherin and Vimentin, whereas downregulation of Snail had no effect on E-cadherin, b-catenin, N-cadherin and Vimentin expression levels in human HCC SNU449 cells (Figure 5f ). Although Snail and Slug are known as CLDN repressors in epithelial cells, treatment with siRNA targeting of Slug, Snail including Zeb1 did not change expression levels of CLDN1 in HCC SNU449 cells. Notably, downregulation of Slug led to a decrease of Zeb1 expression, indicating that Zeb1 expression is regulated by Slug. In line with these results, treatment with siRNA targeting of CLDN1 caused to increase epithelial cell marker E-cadherin, b-catenin and decrease mesenchymal cell markers Vimentin, N-cadherin and EMT regulator Slug in human HCC cell line, SNU449 (Figure 5g) . Also, downregulation of CLDN1 caused to decrease expression of Slug and Zeb1, but not Snail, at the mRNA levels in HCC SNU449 cells (Supplementary Figure S3C) . In addition, downregulation of CLDN1 inhibited ERK phosphorylation, indicating that CLDN1 is necessary for ERK signaling (Table 1) . Notably, CLDN1 was stained more positively in high grade (III, IV grade) of HCC tissues with 82% (37 of 45 tissues), compared with 64% (34 of 53 tissues) in lower grade (I, II grade). Also, the percentage of co-staining of CLDN1 and Slug was slightly higher in high-grade HCC tissues with 53% (24 of 45) than 42% (22 of 53) in low-grade HCC tissues. Taken together, these data suggest that the expression levels of CLDN1 and Slug have correlation with human HCC malignancy. Additionally, CLDN1 may upregulate Slug through cAbl-Ras-Raf-1-ERK signaling axis, resulting in co-expression of CLDN1 and Slug in HCC tissues with a high incidence.
DISCUSSION
Metastasis stands as a major obstacle to improving the prognosis of HCC patients and is a leading cause of mortality. For this reason, understanding the molecular basis for the spread of cancer is one of the most pressing issues in cancer research. However, little is known about how cells acquire invasive properties during metastatic progression.
In this study, we found that the tight junction protein, CLDN1, promotes invasiveness in normal liver cells and human HCC cells. Thus, this study and our previous findings suggest that, far from being the simple sealing proteins once envisioned, CLDNs directly participate in the molecular signaling pathways that lead to metastasis. Overexpression of CLDN1 in normal liver cells induced EMT through upregulation of the transcription factors Slug and Zeb1, thereby promoting invasiveness in both normal liver cells and HCC cells. Notably, CLDN1-mediated EMT was triggered by activation of c-Abl, a non-receptor tyrosine kinase that is involved in a variety of cellular processes, including regulation of actin cytoskeletal dynamics, 22 cell cycle progression, 23 and the apoptotic/cell cycle arrest response to stress. 24, 25 Our findings support previous studies showing that c-Abl regulates the invasive activity of aggressive breast cancers 26, 27 and thyroid cancer cells, 28 and is involved in growth factor-induced cell migration and invasion. 29 Likewise, in this study, we found that c-Abl is activated in liver cells overexpressing CLDN1 and is associated with the 30 showed that EMT-mediated cadherin switching is necessary for increased invasiveness but is not necessary for the morphological changes. Zhou et al. 31 found that KAI1 expression is involved in invasiveness of HCC cells without obvious differences in cell shape.
Tight junction proteins are involved in a variety of cellular processes that regulate polarity, differentiation and migration-all of which are central to cancer progression. An appreciation of this connection has drawn increasing research attention to the role of tight junction proteins and other cell-cell adhesion proteins in cancer. 32, 33 Most work to date has focused on adherens junction proteins, such as cadherins, in cancer progression; in fact, loss of E-cadherin is a defining feature of lobular breast carcinoma. 34, 35 Although the involvement of tight junction proteins in tumor malignancy has been less intensively investigated, recent studies have shown that CLDNs are aberrantly expressed in diverse types of human cancers, including HCCs. 18, 19 In previous studies, abnormal expression of CLDN4 or CLDN7 was shown to correlate with liver metastases. [36] [37] [38] Downregulation of CLDN2 has been implicated in the development and progression of breast carcinomas. 39 Also, expression of CLDN3 and CLDN4 has been shown to be upregulated in invasive breast cancer, 40 whereas the expression of CLDN1 and CLDN7 were downregulated. [40] [41] [42] However, correlation of CLDN1 expression levels with tumor malignancy remains unknown. Although partial or total loss of CLDN1 expression correlates with an increase of malignant potential and with recurrence of disease, Myal et al. 43 found that CLDN1 expression is significantly associated with the basallike subtype of breast cancers, an aggressive subtype of breast cancer associated with the worst prognosis, suggesting that CLDN1 functions both as a tumor suppressor and a tumor enhancer/facilitator. 43 In this context, we found that aberrant expression of CLDN1 was correlated with the invasiveness of HCC cells. Moreover, our study suggests that abnormal expression of the tight junction protein, CLDN1, in HCCs is not a consequence of cancer progression that develops in parallel with an increase in invasiveness; instead, CLDN1 directly participates in the molecular signaling pathways that contribute to tumor malignancy. In this study, downregulation of CLDN1 attenuated the c-Abl-Ras-Raf-1-ERK signaling axis, ultimately decreasing the EMT-regulators Slug and Zeb1 and suppressing the invasiveness of HCC cells. Consistent with this observation, downregulation of c-Abl or inhibition of ERK signaling in HCCs decreased expression of Slug and Zeb1, preventing EMT and decreasing invasive behavior. In this study, downregulation of Slug led to a decrease of Zeb1 expression, supporting the previous study that the transcriptional activity of Zeb1 is increased by Slug. 44 In contrast, the expression levels of Snail, another EMT-regulating transcription factor, were not affected by downregulation of CLDN1 or c-Abl, or inhibition of ERK signaling.
In summary, our study suggests that CLDN1 has a causal role in liver cell invasion. By modulating CLDN1 expression, we found Claudin-1 promotes epithelial-mesenchymal transition Y Suh et al that CLDN1 is both necessary and sufficient to induce the EMT-regulating transcription factors Slug and Zeb1 through the c-Abl-Ras-Raf-1-ERK signaling axis, and eventually promote EMT in HCC cells. Our observations raise the possibility that CLDN1 could be exploited as a potential diagnostic and prognostic biomarker for liver cancer progression, and might provide an important target for therapeutic intervention.
MATERIALS AND METHODS
Cell culture and transfection
Human hepatocellular-carcinoma cell lines, SNU-354, SNU-398, SNU-423, SNU-449, SNU-475, and Chang, were established from the primary tumors of Korean patients. 45 HCCs and normal Chang cells were grown in RPMI 1640 supplemented with 10% fetal bovine serum, penicillin (1000 units/ml) and streptomycin (1000 mg/ml) in a humidified 5% CO 2 atmosphere. The full-length CLDN1 cDNA was cloned into the pcDNA3. Transient transfections were performed using Lipofectamine Plus reagent (Invitrogen, Carlsbad, CA, USA).
Chemical reagents and antibodies ERK inhibitor (U0126), p38 MAPK inhibitor (SB239063) and JNK inhibitor (SP600125) were purchased from Calbiochem (San Diego, CA, USA). Growth factor reduced (BD Matrigel matrix) was obtained from BD Biosciences (San Jose, CA, USA). Polyclonal antibodies to phospho-ERK1/2 (Thr202/Tyr204), phospho-p38 (Thr180/tyr182), ERK1/2, phospho-p38, p38, phospho-JNK1/2 (Thr183/tyr185), b-catenin, g-catenin, E-cadherin, N-cadherin and Snail were obtained from Cell Signaling Technology (Beverly, MA, USA). a-catenin was obtained from Abcam (Cambridge, MA, USA). Polyclonal antibodies to Snail, Zeb1, JNK2 and c-Abl were purchased from Santa Cruz (Santa Cruz, CA, USA). Vimentin antibody was purchased from NEO MARKERS (Fremont, CA, USA). Myelin basic protein were purchased from Upstate Biotechnology, Inc. (Lake Placid, NY, USA). Agarose beads was purchased from Millipore (Billerica, MA, USA). Anti-mouse Alexa Fluor 488 was purchased from Invitrogen. 4, 6-diamidino-2-phenylindole and monoclonal antibody to b-actin were obtained from Sigma (St Louis, MO, USA).
Transduction with small hairpin RNA Lentiviral constructs encoding small hairpin RNA targeted to human CLDN1 and scrambled small hairpin RNA were purchased from OriGene Technologies, Inc. (Rockville, MD, USA). Cells (293T) were seeded (3 Â 10 6 cells/ml) in 60-mm dish and viral particles were generated by transfection as described previously. 46, 47 Viral supernatant was collected B65 h after transfection and was used for transduction. Cells were infected for 24 h and were then treated with 1 mg/ml puromycin to eliminate uninfected cells. Media was then replaced after 2 days, and cells were collected for implantation to athymic Balb/c female nude mice (5 weeks of age).
Invasion assay
Cells (2.5 Â 10 4 cells) were suspended in 100 ml DMEM (Dulbecco's modified Eagle's medium) containing 1% fetal bovine serum. For invasion assay, the cells were loaded into the upper well of the Transwell-chamber (8 mm pore size; Corning, Corning, NY, USA) that was pre-coated with 10 mg/ml growth factor reduced Matrigel (BD Biosciences) on an upper side of the chamber with the lower well filled with 0.8 ml of DMEM containing 10% fetal bovine serum. After incubation for 48 h at 37 1C, noninvaded cells on the upper surface of the filter were removed with a cotton swab, and migrated cells on the lower surface of the filter were fixed and stained with a Diff-Quick kit (Fisher Scientific, Pittsburgh, PA, USA) and photographed (magnification: Â 20). Invasiveness was determined by counting cells in five microscopic fields per well, and the extent of invasion was expressed as an average number of cells per microscopic field. Cells were imaged with by phase-contrast microscopy (Leica Microsystems, Bannockburn, IL, USA).
Soft agar colony formation assay
To examine anchorage-independent growth, a cell suspension (2 Â 10 4 cells) were suspended in 0.4% agar in growth medium and seeded in triplicate on 60-mm dishes pre-coated with 0.8% agar in growth medium and incubated at 37 1C, 5% CO 2 . After 12-30 days, colonies were photographed and counted in four randomly chosen fields and expressed as means of triplicates, representative of two independent experiments.
Transfection with siRNA Cells were transfected with siRNA duplexes (40 nM) by using Lipofectamine 2000 (Invitrogen), following the procedure recommended by the manufacturer. All si-RNA targeting of CLDN1 (5
, c-Abl (5 0 -GGA AGA GUU CUU GAA AGA ATT-3 0 ) and a negative control siRNA were purchased from Genolution Pharmaceuticals, Inc (Seoul, Korea).
Western blot analysis
Cell lysates were prepared by extracting proteins with lysis buffer (40 mM Tris-HCl (pH 8.0), 120 mM NaCl, 0.1% Nonidet-P40) supplemented with protease inhibitors. Proteins were separated by SDS-PAGE, and transferred to a nitrocellulose membrane (Amersham, Arlington Heights, IL, USA). The membrane was blocked with 5% non-fat dry milk in Tris-buffered saline, and incubated with primary antibodies for overnight at 4 1C. Blots were developed with a peroxidase-conjugated secondary antibody, and proteins visualized by enhanced chemiluminescence procedures (Amersham), using the manufacturer's protocol.
Immunocytochemistry
Cells were fixed with 4% paraformaldehyde and permeabilized with 0.1% Triton X-100 in phosphate-buffered saline (PBS). Following cell fixation, cells were incubated with the appropriate primary antibodies in a solution of PBS with 1% bovine serum albumin and 0.1% Triton X-100 at 4 1C overnight. Antibodies used were as follows: human anti-b-catenin (mouse polyclonal antibody, 1:200), N-cadherin (mouse polyclonal antibody, 1:200). Stainings were visualized using anti-mouse Alexa Flour 488 (Molecular Probes, Seoul, Korea). Nuclei were counterstained using 4, 6-diamidino-2-phenylindole (Sigma). Stained cells were visualized with a fluorescencemicroscope (Olympus IX71, Olympus, Tokyo, Japan).
Immunohistochemistry
HCC tissue array with corresponding normal tissues (AccuMax Array, ISU ABXIS and CSA4 Human, Liver cancer-normal, Super Bio Chips) were stained by using Vectastain Elite ABC kit (PK-6101, Vector Laboratories, Burlingame, CA, USA). The rabbit anti-CLDN1 and -Slug antibody diluted 1:1000 in blocking solution was applied to the sections and incubated at 4 1C for overnight. In the negative control, rabbit IgG (ab27478, Abcam) was used instead of primary antibody. After washing in PBS, 1:200 dilution of biotinylated goat anti-rabbit IgG antibody in blocking solution was applied to the sections and incubated for 30 min. After washing in PBS, ABC reagent was applied to the sections and incubated for 30 min. After washing in PBS, color reaction was performed with 3, 3 0 -diaminobenzidine (Vector Laboratories) and slides were washed with PBS. After counterstaining with hematoxylin and clearing with graded ethanol series and xylene, the sections were mounted with Canada balsam. Observation and photography were conducted using IX71 microscope (Olympus) equipped with DP71 digital imaging system (Olympus).
Activated Ras affinity precipitation assay Activated Ras affinity precipitation assays were performed according to the manufacturer's protocol. Briefly, cell lysates were incubated with 5 mg of Raf-1 Ras-binding domain agarose beads (Millipore) for 30 min at 4 1C. After extensive washing of the agarose beads three times with washing buffer (25 mM HEPES (pH 7.5), 10 mM MgCl 2 , 150 mM NaCl, 1 mM EDTA, 1% Nonidet P-40, 1 mM Na 3 VO 4 , 10% glycerol, 10 mg/ml leupeptin, 10 mg/ml aprotinin and 25 mM NaF), the activated Ras (GTP-Ras) bound to Raf-1 Rasbinding domain agarose beads (Millipore) was released by addition of SDS-PAGE sample buffer. The amount of activated Ras was determined by immunoblotting with a monoclonal pan-Ras antibody.
Immune complex kinase assay
Proteins from cell extracts were immunoprecipitated with primary antibody at 4 1C for 4 h. The immunoprecipitates were washed twice kinase reaction buffer (50 mM HEPES (pH7.5), 10 mM MgCl 2 , 1mM
Claudin-1 promotes epithelial-mesenchymal transition Y Suh et al dithiothreitol, 2.5 mM EGTA, 1 mM NaF, 0.1 mM Na 3 VO 4 and 10 mM glycerophosphate), and then resuspended in 20 ml of kinase reaction buffer. The kinase assay was initiated by adding 20 ml of kinase reaction buffer, containing 10 mg of substrate and 2 mCi of [g-32P]ATP (ICN). The reactions were carried out at 30 1C for 30 min, and terminated by adding SDS sample buffer, and the mixtures were boiled for 5 min. The reaction products were analyzed by SDS-PAGE and autoradiography.
Statistical analysis
All experimental data are reported as mean and the error bars represent the s.d. Statistical analysis was performed by the non-parametric Student's t-test. Contingency table analysis was performed using GraphPad Prism (5.0) software.
ABBREVIATIONS
EMT, epithelial-mesenchymal transition RNA; PI3K, phosphoinositide 3-kinase; siRNA, small interfering.
